Background and aim This is a follow-up study of a previously published randomized clinical trial conducted in Norway
INTRODUCTION
Treatment is the most important factor to prevent overdose death and other harmful effects of opioid abuse [1] . Opioid agonist maintenance treatment (OMT) is the World Health Organization (WHO) recommended option [2] . Despite the effectiveness of OMT [3] and its availability in many countries, it is utilized only by half of people with opioid dependence in Europe [4] . There are opioid-dependent adults who prefer not to receive OMT with opioid agonist medications, and may consider opioid antagonist treatment an alternative [5] [6] [7] .
Naltrexone is an opioid antagonist that competitively blocks euphoric effects of heroin and other opioids, thereby preventing relapse of opioid abuse and overdose deaths when used as prescribed [8] [9] [10] [11] . It also reduces the craving for opioids and alcohol [12, 13] . Sustained-release formulations of naltrexone, both implantable and injectable, have shown promising results in maintaining abstinence from opioids and acceptable retention rates in studies with durations up to 6 months [14] [15] [16] [17] [18] [19] . An injectable form of extended-release naltrexone (XR-NTX) administrated once monthly is approved in the United States and in Russia [14, 20, 21] . Two recently published randomized clinical trials (RCT) from Norway and the United States compared the effectiveness of XR-NTX to buprenorphine-naloxone (BP-NLX) [22, 23] . In the intention-to-treat population, the US study found BP-NLX to be superior to XR-NTX, due mainly to XR-NTX induction failure [22] . In the Norwegian study, which recruited participants after successful opioid detoxification and among the participants who were inducted successfully on study medication in the US study, similar retention, effectiveness and safety outcomes were reported [22, 23] .
The data on long-term use of XR-NTX are limited [3, 24] . In a Russian trial, 62.3% of 114 participants completed 1-year follow-up [9] . In an American study, 55% of 38 health professionals received 12 XR-NTX injections [25] . In comparison, a review found retention rates between 26 and 85% at 12-month follow-ups for patients in opioid agonist treatment [24] . Sustained-release formulations of naltrexone are considered well-tolerated, with few serious side effects [11, 21, 26, 27] . Severe injection-site reactions that require surgery may occur, but are not reported frequently [21] . Studies of sustained-release formulations of naltrexone have been criticized for the lack of post-treatment reporting of adverse events, including overdoses [28, 29] . A recent study found no significant differences in rates of overdoses among people with opioid dependence treated with opioid agonist treatment or naltrexone implants, including after treatment cessation [30] .
Previous research on XR-NTX has been conducted mainly in countries where OMT has a limited availability due to structural barriers; e.g. in Russia, where OMT medication is illegal, or in populations where access is limited because the patients are responsible for treatment costs [3, 14, 25, 31] . To evaluate the clinical potential of XR-NTX in settings where OMT is available at no cost, studies with longer follow-ups are needed [3, 32, 33] .
The overall purpose of the study was to assess the effectiveness, safety and feasibility of longer-term treatment with XR-NTX in a clinical setting. We aimed to: (1) compare participants continuing on XR-NTX following the 3-month RCT for potentially up to 12 total months treatment with those inducted on XR-NTX after the RCT for potentially up to 9 months treatment, and completers with non-completers with respect to (a) retention in XR-NTX treatment during a 9-month period, (b) opioid use, (c) craving scores and (d) treatment satisfaction; and (2) compare participants continuing XR-NTX with those inducted on XR-NTX with respect to (a) use of other substances; (b) addiction-related problems and (c) reported adverse events.
According to the study protocol, participants could choose between receiving BP-NLX or XR-NTX during the 9-month follow-up period. Of the 122 participants who entered the follow-up, only five chose further treatment with BP-NLX while 117 chose XR-NTX. While OMT (including BP-NLX) is available at no cost in Norway, XR-NTX was only available through this study. The opportunity to receive XR-NTX was probably the most important motivating factor for study participation [23] . Due to the low number of participants choosing BP-NLX, no meaningful statistical or clinical comparisons could be performed using this group of five, leaving the 117 participants receiving XR-NTX as the natural focus of investigation. The rationale for comparing participants who continued XR-NTX to those inducted on XR-NTX was to investigate the clinical feasibility of XR-NTX induction. Participants who preferred BP-NLX were followed up at their sites' OMT clinics according to the national OMT guidelines.
METHODS
In the aforementioned Norwegian multi-centre RCT, 159 people with opioid dependence were randomized to receive XR-NTX or BP-NLX in a 1 : 1 ratio, after being tapered to a maximum of 4 mg buprenorphine [23] . Retention rates were non-inferior in the two groups and 105 completed the 3-month study (Fig. 1) . Superiority analyses showed significantly lower use of illicit opioids and lower craving scores in the XR-NTX group. No significant differences were found between the treatment groups regarding most other illicit substance use. In the XR-NTX group, more adverse events were reported [23] .
Design
This 9-month prospective cohort study was conducted following the 3-month RCT [34] . Participants consented to participate in the follow-up at conclusion of the RCT. In order to estimate effectiveness, safety and feasibility of XR-NTX in longer-term participants continuing XR-NTX (n = 54) and participants inducted on XR-NTX (n = 63) were compared with regard to retention in treatment, substance use, adverse events and other relevant outcomes (see below) every 4 weeks during the 9-month study period [23] .
Setting
During the period from November 2012 to July 2015, opioid-dependent individuals were recruited for study participation in the RCT from five urban hospitals in Norway. RCT participants were offered to continue participation in the follow-up at week 12. Participants dropping-out of any treatment arm during the RCT period, but motivated for re-inclusion, were allowed induction on XR-NTX after week 12. The follow-up study was completed when the last patient completed participation in July 2016.
Participants
Eligible participants were opioid-dependent men and women aged 18-60 years. Exclusion criteria were alcohol dependence or serious somatic or psychiatric illnesses regarded as contra-indications for study participation. Women could not be pregnant or breastfeeding and had to use contraception during the study.
Measurements and outcomes
Participants were interviewed every fourth week using the Addiction Severity Index, European version [35] and selfreported craving for opioids and treatment satisfaction. Data were collected using the time-line follow-back method [36] . Any adverse events occurring during the study period and for up to 3 months after study discontinuation were reported.
Outcomes were: retention in treatment, measured in numbers of weeks in treatment and the number of participants completing the study; the number of participants abstinent from opioids during the study; the use of heroin and other illicit opioids, the use of cannabis, amphetamines and benzodiazepines; heavy alcohol use; injection use; acquisitive crime and work, measured in number of days within the 4 weeks preceding each study attendance; money spent on drugs and alcohol within the 4 weeks preceding each study attendance, measured in Norwegian crowns (NOK); craving for heroin and treatment satisfaction within the 4 weeks preceding each study attendance measured by a visual analogue scale (VAS) with scores from 0-10; and the number of reported adverse events [34] .
Study intervention
After week 12, participants chose medication based on their preferences. Those preferring XR-NTX are referred to in this paper: participants already receiving XR-NTX in the RCT continued their treatment. Participants who changed from BP-NLX to XR-NTX and those re-included in the study and inducted on XR-NTX in the follow-up were referred to a detoxification unit at week 12. The majority of participants were administered BP-NLX and tapered with a flexible standard 2 mg/day regimen. A small number of participants chose to discontinue opioid agonists without any tapering. After a minimum of 72 hours without any intake of opioids and if passing an injection of a 0.4 mg naloxone test dose, participants were given an intramuscular injection of 380 mg XR-NTX (Vivitrol ® ) in the buttock [34] . To relieve withdrawal symptoms such as vomiting, chills and insomnia in the detoxification phase, participants were prescribed pharmacological Figure 1 Flow-chart for participants included in the study; participant flow in the preceding 3-month randomized controlled trial (RCT) [23] and in the present 9-month follow-up study. XR-NTX = extended-release naltrexone; BP-NLX = buprenorphine-naloxone treatment such as benzodiazepines, metoclopramide, valproate, quetiapine, clonidine and pregabalin, adapted individually according to clinical assessment. Participants were discharged from the detoxification units 1-7 days after the initial XR-NTX dose. Following induction, participants received a XR-NTX injection in an out-patient setting every fourth week throughout the study period. Counselling was not mandatory, but was offered to all participants at the study site as part of standard ancillary services. Counselling was adapted individually by clinicians at the OMT clinics or other out-patient clinics, as often as once every week but typically once or twice a month.
Research ethics
The study was approved by the South-East Regional Ethical Board for Medical Research Ethics (no. 2011/1320) and by the Norwegian Medicines Agency.
All participants were given verbal and written information about the study, including possible effects and sideeffects of study medication before assigning the written informed consent [37] . Except for travel expenses, participants were not paid or compensated for taking part in the study.
The participants were able to withdraw from the study at any time. Participants who failed to attend follow-ups and did not respond to at least three attempts at communication during the ensuing week were reported as lost-to-follow-up in the study. Participants were informed of the increased risk of overdoses after discontinuing XR-NTX. All participants were required to accept enrolment into the local OMT programme to ensure adequate follow-up and rapid access to opioid agonist treatment in the event of dropout from the study.
Statistical analyses
Statistical analyses were performed to compare outcomes between the participants continuing XR-NTX treatment (n = 54) and the participants inducted on XR-NTX (n = 63) and between completers and non-completers, in total 117 participants who received at least one injection of XR-NTX during weeks 12-48. Data were described as means and confidence intervals (CI) or frequencies and percentages. Kaplan-Meier survival curves were plotted and log-rank test performed to assess retention in treatment.
Differences between groups in 9-month changes in substance use, addiction-related outcomes and treatment satisfaction were assessed by linear mixed models with random effects for time and participants nested within sites. Fixed effects for time up to third-order handling non-linear patterns were included together with participant group and interaction between the group and time. A significant interaction would imply a difference in change between the groups. The results were presented as observed means and 95% CI, and mean differences with 95% CI and P-values derived from linear mixed models.
Differences in the number and type of adverse events between the participants who continued on XR-NTX and those inducted on XR-NTX in the follow-up study were described using Fisher's exact test.
Results with P-values < 0.05 were considered significant and all tests were two-sided. Analyses were performed using SPSS version 24 and SAS version 9.4.
RESULTS
Of the 143 participants who received at least one dose of study medication in the RCT, 117 (81.8%) chose XR-NTX treatment in the follow up study; 54 continued on XR-NTX, 43 changed from BP-NLX to XR-NTX, while 20 were re-included in the follow-up and inducted on XR-NTX after having dropped out of the RCT previously (Fig. 1) .
Among the 117 participants, 89 were men and 28 were women. The mean age was 35.6 years. Prior to study inclusion, 63.2% of the participants reported heroin as their primary problem substance, 12.0% reported other opioids and 24.8% reported polydrug use, including opioids (Table 1) .
Retention
After 9 months, 58 participants (49.6%) had attended all scheduled visits and received XR-NTX injections as prescribed (Fig. 2) , meaning that 28 participants who continued XR-NTX (51.9%) completed a total of 12 months XR-NTX treatment and 30 who were inducted on XR-NTX (47.6%) completed a total of 9 months XR-NTX treatment (Fig. 1) . The mean (95% CI) number of weeks in treatment in the follow-up was 25.6 (22.3-29.0) and 25.4 (22.4-28.4) among participants continuing XR-NTX and those inducted on XR-NTX, respectively, with no differences in retention between groups.
Non-completers (n = 59) conveyed different reasons for discontinuing the study: 35 (59.3%) were lost to follow-up, 14 (23.7%) wanted to manage without any medication or disliked the effect of XR-NTX, seven (11.9%) reported adverse events (see below), two (3.4%) reported serious adverse events and one (1.7%) died in an accident.
Use of opioids
There were no significant differences in the use of heroin or other illicit opioids between participants continuing XR-NTX and participants inducted on XR-NTX. The reduction from week 12 in heroin (other illicit opioids) use was significant to week 36 (week 24) among those continuing and week 48 (week 36) among those inducted on XR-NTX. During the 9-month study, 53.7% (29 of 54) of participants continuing XR-NTX treatment, and 44.4% (28 of 63) of participants inducted on XR-NTX reported abstinence from all opioids. Differences in heroin use were not significant between completers and non-completers, with completers reporting significant reduction in heroin use to week 32, while the reduction among non-completers was significant to week 24. However, completers and non-completers differed significantly in use of other opioids (P = 0.018), where non-completers reported significantly higher use than completers up to week 16. Moreover, reduction in use of other illicit opioids was significant to week 16 among completers and to week 40 among noncompleters. See Table 2 and Fig. 3 for more details.
Other outcome measures
There were significant differences between participants continuing XR-NTX treatment and those inducted on Characteristics of the 117 people with opioid dependence who received extended-release naltrexone (XR-NTX) in the study; n = 54 continuing XR-NTX treatment after an initial 3-month randomized controlled trial (RCT) and 63 who were inducted on XR-NTX during the 9-month follow-up. Data collected at the time of inclusion in the RCT, week 0.
a Reported mean differences with corresponding 95% confidence intervals or number and percentage.
XR-NTX in heavy alcohol use (P = 0.045) and days of work (P = 0.016), where those inducted on XR-NTX reported more heavy alcohol use and more days at work at the end of the study period. Both groups reported a significant reduction in money spent on drugs up to week 32. No other differences or significant changes were found (Table 2) . Those inducted on XR-NTX reported significantly more heroin craving than participants continuing XR-NTX treatment (P = 0.009), but reduction in heroin craving was only significant to week 16 among those inducted on XR-NTX. Participants continuing XR-NTX treatment reported higher satisfaction with the treatment (P < 0.001), which was increasing to week 24 in both groups. No differences in heroin craving or treatment satisfaction were found between completers and noncompleters, with heroin craving remaining stable and treatment satisfaction increasing until week 24 in both groups (see Fig. 3 ). Comparing number of days with substance use and addiction-related problems during the last 4 weeks between participants continuing extended-release naltrexone (XR-NTX) treatment and participant inducted on XR-NTX in the follow-up. a Mean and confidence intervals (CIs) are descriptive numbers, not adjusted for repeated measurements or site effect; b mean differences with corresponding 95% CIs and P-values are derived from linear mixed models, adjusted for intraparticipant and intrasite correlations.
Safety and tolerability
A total of 62 (53%) participants reported at least one nonserious adverse event (Table 3) . Participants inducted on XR-NTX reported 37 and participants continuing XR-NTX reported 25 adverse events (P = 0.198).
A total of 37 participants reported two to 15 different adverse events, most frequently withdrawal-like symptoms reported by the participants who were inducted on XR-NTX in the follow-up. Other adverse events were infections, non-serious injuries and various pain conditions. Injectionsite problems and withdrawal-like symptoms were considered to be related to XR-NTX.
Adverse events caused seven participants to discontinue treatment due to: withdrawal-like symptoms (two), psychological reactions (two), need for opioid agonist pain treatment (one), seizure (one) and insomnia (one).
Five participants reported a serious adverse event requiring hospitalization; two due to infections, one planned surgery and two serious injection-site reactions requiring surgery. All participants recovered completely, and except for those who experienced the injection-site reactions, all continued XR-NTX treatment. One participant died of internal injuries after an accident. No opioid overdoses were reported. No serious adverse events, including no overdose fatalities, were reported among the participants during the first 3 months following their completion of the study.
DISCUSSION
Of the 143 participants who took at least one dose of study medication in the 3-month RCT, 117 (81.8%) chose to continue on XR-NTX or be inducted on XR-NTX in the 9-month follow-up study. Only five participants (3.5%) chose to either continue on BP-NLX or transition from XR-NTX to BP-NLX in the follow-up. As BP-NLX is available in Norway at no cost in the OMT programmes, while . *Significant differences between completers and non-completers, P < 0.05; **significant differences between completers and non-completers, P < 0.01; ***significant differences between completers and non-completers, P < 0.001; $ significant differences between 'continuing extended-release naltrexone (XR-NTX)' and 'inducted on XR-NTX', P < 0.05; $$ significant differences between 'continuing XR-NTX' and 'inducted on XR-NTX', P < 0.01; $$$ significant differences between 'continuing XR-NTX' and 'inducted on XR-NTX', P < 0.001.
XR-NTX was not registered for use and available only for study participants, it is likely that study participation was motivated by the possibility to obtain XR-NTX [23] . Half the participants (49.6%) completed all XR-NTX injections and follow-up interviews in the 9-month study, and no differences were reported between participants continuing XR-NTX and those inducted on XR-NTX. There was no difference in opioid use between the groups, and a nonsignificant reduction in opioid use was reported during the study. Abstinence from opioids was reported by 53.7% of those continuing and 44.4% of those inducted on XR-NTX. During the 9 months, participants inducted on XR-NTX reported significantly more days with heavy alcohol use and more days working than participants who continued XR-NTX. Participants continuing XR-NTX reported significantly less heroin craving and higher treatment satisfaction than those inducted on XR-NTX. Adverse events were reported by 53% of the participants, and the majority of these were related to withdrawal symptoms during induction on XR-NTX.
Retention rates reported in studies of medicationassisted treatment for opioid dependence vary considerably, e.g. between 26-85% at 1-year follow-ups in OMT [24] . In our study, 49.6% of the participants completed the followup with XR-NTX, and thus within the range of findings in studies of OMT. Two studies of XR-NTX reported retention rates of 55 and 62.3% after 1 year in treatment [9, 25] . Differences in study designs, the availability of OMT medication and the inclusion criteria limit comparison between our study and previous studies of XR-NTX. The study design did not include any mandatory supplementary interventions. We suggest that implementing such interventions could improve retention in XR-NTX treatment. In contrast to the findings from a longer-term study in Russia, we found no differences in the retention rates between participants who continued on XR-NTX from the RCT phase and those inducted on XR-NTX in the follow-up study [9] .
Consistent with other studies of sustained-release naltrexone, participants reported reduced use of illicit opioids during the study period [9, 11, 15, 16, 19, 22, 26, 38, 39] . Fewer participants inducted on XR-NTX reported full abstinence from opioids, and we suggest this may be a result of participants 'testing the blockade' when starting the XR-NTX treatment, as seen in other studies [10] . Opioid use remained at a low level in both groups (Table 2) .
Similar to the preceding RCT phase [23] and other XR-NTX studies [19, 25] , the majority of the adverse events were withdrawal-related and reported following the first administration of XR-NTX [21] . While we administered the first XR-NTX injection after a minimum 72 hours of complete abstinence from any opioids, other studies have recommended a longer period of abstinence [9, 40, 41] . Extending the number of opioid-free days would have reduced the amount of adverse events and eased the induction phase. However, while participants were encouraged to extend the number of opioid-free days, some expressed concern they would not be able to endure more than 72 hours without opioids and requested a rapid but more unpleasant induction. As XR-NTX was only available No serious adverse events were reported during the first three months after the study discontinuation. through study participation and participants volunteered for complete abstinence from opioid agonists, this may have enhanced participants' motivation to complete the induction phase.
No opioid overdoses were reported during the study or within 3 months after study discontinuation. This may reflect the effectiveness of XR-NTX in blocking the opioid receptors and thereby preventing overdoses [20] , as well as being an indication of the participants' high motivation for an opioid-free treatment. The safety profile of XR-NTX in our study corresponded with previous findings in other longer-term studies [9, 25] .
The naturalistic setting of the study may provide additional knowledge about the utilization of XR-NTX outside a study context. We regard the generalizability from this study to be acceptable to locations where the health-care system and the regulatory framework on OMT correspond to the system in Norway or similar western European countries.
This study has several limitations: the open-label design without blinding and the loss of a relevant control group may reduce the validity of the study and limit our ability to draw conclusions regarding efficacy [42] . The nonavailability of XR-NTX in Norway accounted for most participants choosing XR-NTX in the follow-up and, thus, the loss of a control group. However, we considered the observational design appropriate to achieve the objectives of this study, which was to assess the longer-term clinical effectiveness, safety and feasibility of XR-NTX. The lack of urine drug testing (UDT) is a limitation, thus self-reported drug use could not be confirmed. In the RCT, reported use of drugs corresponded with UDT results at an acceptable level [23] . Attrition due to high dropout rates is a weakness of this study, similar to other longer-term studies [32] .
In summary, there were no differences between participants continuing XR-NTX and participants inducted on XR-NTX in this 9-month follow-up study concerning retention in treatment and use of opioids, suggesting feasibility for induction and continuation of XR-NTX treatment in a clinical setting.
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